Theralase TechnologiesTLTFF +1.22%46 Gross Margin % is 48.45% as of Mar. 2026, which is 11% below its 10-year median of 54.15. GuruFocus rates TLTFF with a GF Score™ of 46/100 and a GF Value™ of $0.13 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Theralase Technologies ranks better than 70.68% on this metric.
TLTFF's Gross Margin % is ranked better than 70.68% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 52.07
vs TLTFF: 64.96
Theralase Technologies had a gross margin of 48.45% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Theralase Technologies was 14.20% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Theralase Technologies had a gross margin of 48.45% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Theralase Technologies Gross Margin % Related Terms
Theralase Technologies Gross Margin % Historical Data
* Premium members only.
The historical data trend for Theralase Technologies's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theralase Technologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Theralase Technologies (TLTFF) has a Gross Margin % of 48.45% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Theralase Technologies and its competitors. This is 11% below median its historical median of 54.15. Over the past decade, Theralase Technologies' Gross Margin % has ranged from 6.33 to 64.96. According to the industry distribution chart, Theralase Technologies ranks #236 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 29.3%.
Is Theralase Technologies' Gross Margin % too high?
Theralase Technologies' current Gross Margin % of 48.45% is 11% below median its 10-year median of 54.15. Over the past 10 years, this metric has ranged from a low of 6.33 to a high of 64.96. The Medical Devices & Instruments industry median Gross Margin % is 52.07. Theralase Technologies' value of 48.45% is 7% below this industry median. Based on the distribution chart, Theralase Technologies ranks #236 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #236 out of 805 companies for Gross Margin %. This puts Theralase Technologies in the upper half of its industry. The industry median Gross Margin % is 52.07. Theralase Technologies' value of 48.45% is 7% below this benchmark. Historically, Theralase Technologies' own Gross Margin % has ranged from 6.33 to 64.96 over the past decade. While the company's 10-year median is 54.15 vs. the industry median of 52.07, Theralase Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theralase Technologies's current Gross Margin % of 48.45% is 7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current Gross Margin % is 48.45%, which is 11% below median its own 10-year median of 54.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 28.1% above its estimated fair value. The current Gross Margin % is 48.45%, which is 11% below median its 10-year median of 54.15 and 7% below the Medical Devices & Instruments industry median of 52.07. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Gross Margin % is 48.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.17 is trading 28.1% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Modestly Overvalued.
Key valuation signals for TLTFF:
Gross Margin %: 48.45% (11% below median its 10-year median of 54.15)
GF Value™: $0.13 vs. price of $0.17 (28.1% above fair value)
Industry Position: 7% below the Medical Devices & Instruments median (#236 of 805)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score
Get the complete analysis for TLTFF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
